Join the Oncology Voice Network. Join for Free
Value assessment frameworks in oncology: championing concordance through shared standards
ASCO ESMO NHB MCBS

Value assessment frameworks in oncology: championing concordance through shared standards


Share This Article


Summary

The ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), introduced in 2015, are essential tools for assessing the relative benefit of cancer therapies. Both ASCO and ESMO continually refine these frameworks and engage with stakeholders to better understand and communicate the value of new treatments. As the global burden of cancer grows, their collaborative efforts aim to foster a coherent approach to managing and reducing this impact.

As rapidly evolving tools under the constant rigorous review and development by both ASCO and ESMO’s expert task forces, the ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) were both launched in 2015 to assess the relative benefit of cancer therapies and were recently compared. Both societies are working to better understand and measure the value of new cancer therapies and are facilitating a broader discussion with stakeholders that, hopefully, will lead to a coherent approach to confronting the global burden of cancer. The time to do so is now.....
Click for Source Download PDF version
ASCO, ESMO, NHB, MCBS

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Three Leaders, One Vision: Principles for Transforming Cancer Care Delivery
Partner Avatar Monty Pal

Three Leaders, One Vision: Principles for Transforming Cancer Care Delivery

Article
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
OVN Avatar Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Article
Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers
OVN Avatar Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang

Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Explore OVN